Effects of siRNA TMPRSS2-ERG on ERG protein expression and cell viability. by Giorgia Urbinati (554921)

“…<p>VCaP cells were transfected for 24h, 48h and 72h with 50 nM of siRNAs TMPRSS2-ERG III (1, 2, 3), siRNAs TMPRSS2-ERG IV (1, 2), siRNA against ERG wild type or siRNA Control. …”

Three-, bi- and mono-functional Vγ9Vδ2 T-cell subsets decrease in HIV+ patients. by Rita Casetti (608635)

Effects of siRNA TMPRSS2-ERG III and IV on cell death pathways. by Giorgia Urbinati (554921)

Barbie’s ankle equinus measured at 50 degrees as equnius posture (a) and flat foot posture measured at 0 degrees (b), with a handheld goniometer. by Cylie Williams (3446018)

Arginine supplementation decreases the inhibitory effect exerted by 5-flucytosine in <i>C</i>. <i>glabrata</i>. by Catarina Costa (322963)

Spatial information is significantly decreased in dCA1 and vCA1 in APP/PS1 mice. by Udaysankar Chockanathan (18510288)

“…(B) In dCA1, spatial information was decreased in APP/PS1 mice relative to C57BL/6 controls (mean ± std: C57BL/6 = 0.132 ± 0.048, APP/PS1 = 0.128 ± 0.051, p < 0.005, two-sided Wilcoxon rank-sum test, n_C57BL/6 = 305 units from 5 recording sessions, n_APP/PS1 = 180 units from 4 recording sessions). …”

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer by Giorgia Urbinati (554921)

“…The siRNA against TMPRSS2-ERG fusion variant IV showed the highest anti-proliferative effects: Significantly decreased cell viability, increased cleaved caspase-3 and inhibited a cluster of anti-apoptotic proteins. …”

Low concentrations of siRNA TMPRSS2-ERG III and IV impair TMPRSS2-ERG oncogene and oncoprotein levels but not cell viability. by Giorgia Urbinati (554921)

“…<p>VCaP cells were transfected for 72h from 2.5 nM to 50 nM with siRNA TMPRSS2-ERG III, siRNA TMPRSS2-ERG IV or siRNA Control. …”

Scree plot curve of 50 CIs created by each number of models. by Hitoshi Biwasaka (19923867)

List of mRNAs that are differentially expressed in both the RNAPII ChIP-seq and RNA-seq datasets, mRNAs with decreased expression in both lists, and mRNAs that have decreased expre... by Katherine I. Farley-Barnes (9258036)

“…<p>List of mRNAs that are differentially expressed in both the RNAPII ChIP-seq and RNA-seq datasets, mRNAs with decreased expression in both lists, and mRNAs that have decreased expression in both lists and are also nucleolar in at least 1 database [<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008967#pgen.1008967.ref050" target="_blank">50</a>–<a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.1008967#pgen.1008967.ref052" target="_blank">52</a>].…”

Summary of cell-based assay EC50 results for WT BMP9 and A347E variant. by Tobias G. Schips (21799838)

BMS-754807 decreases AKT phosphorylation in DIPG cell-lines cultured in serum-free media. by Kyle G. Halvorson (699837)

Discrimination of rippled-spectrum patterns in noise: A manifestation of compressive nonlinearity - Fig 6 by Olga N. Milekhina (812701)

Decrease in proliferation after ENU-exposure as decrease in BrdU immunostaining. by Vivian Capilla-Gonzalez (336046)

“…<p>Micrograph of the BrdU+ cells immunolabeled with DAB showed a decrease in the proliferation in the SVZ (B) and DG (D) of treated animals, compared with control group (A and C, respectively). …”

The interaction effect of urinary bisphenol A exposure levels at two time points during childhood on serum thyroid hormone concentrations in adolescence. by Jung Eun Choi (563339)

<i>Aspergillus flavus</i> mRNA expression (a) <i>aflD</i> and (c) <i>aflR</i> and phylogenetic analysis of (b) <i>aflD</i> and (d) <i>aflR</i> after exposure to 50 mg/mL of <i>U. e... by Martha Cebile Jobe (21175426)

Graphs showing average growth cone area of control, 0.5% stretched, 5% stretched and repetitive very mild (2×0.5%) stretched axons at different time point. by Yiing C. Yap (4003037)

Detection of S. pneumoniae in children younger than 5 years with AOM in Europe between 2011-2021(% and sample size). by Heloisa Ricci Conesa (18291210)

Subjects:

Evaluation of long-term efficacy of PCSK9 vaccine (N = 5–7). by Ryo Kawakami (4849549)

Effects of A1AR expression on response to hypoxia at E9.5 and E12.5. by Daniela L. Buscariollo (140729)

“…<p>A: At E9.5, responses to hypoxia in A1AR −/− (n = 15) and A1AR +/− (n = 50) embryos were studied. …”